BioNTech (UK) Today
| 0A3M Stock | 103.55 1.23 1.20% |
Performance7 of 100
| Odds Of DistressLess than 32
|
BioNTech is selling for under 103.55 as of the 22nd of November 2024; that is 1.20 percent increase since the beginning of the trading day. The stock's lowest day price was 103.55. BioNTech has about a 32 percent probability of financial distress in the next few years of operation and did not have a very good performance during the last 90 trading days. Equity ratings for BioNTech SE are calculated daily based on our scoring framework. The performance scores are derived for the period starting the 26th of May 2024 and ending today, the 22nd of November 2024. Click here to learn more.
Business Domain Commercial & Professional Services | Classification Industrials |
BioNTech is entity of United Kingdom. It is traded as Stock on LSE exchange. More on BioNTech SE
Moving against BioNTech Stock
Follow Valuation Profit Patterns Odds of Bankruptcy
Check how we calculate scores
BioNTech Stock Highlights
Most reasonable investors view market volatility as an opportunity to invest at a favorable price or to sell short against a bearish trend. BioNTech's investment highlights are automatically generated signals that are significant enough to either complement your investing judgment regarding BioNTech or challenge it. These highlights can help you better understand the position you are entering and avoid costly mistakes.
| CEO CoFounder | Ugur MD |
| Business Concentration | Environmental & Facilities Services, Commercial & Professional Services, Industrials, Industrials, Commercial Services & Supplies, Commercial & Professional Services, Industrials (View all Sectors) |
BioNTech SE (0A3M) is traded on London Exchange in UK and employs 6,133 people. BioNTech is listed under Environmental & Facilities Services category by Fama And French industry classification. The company operates under Commercial Services & Supplies sector and is part of Industrials industry.
BioNTech generates positive cash flow from operations, but has no cash available
Check BioNTech Probability Of Bankruptcy
Ownership AllocationBioNTech SE shows majority of its outstanding shares owned by insiders. An insider is usually defined as a corporate executive, director, member of the board or institutional investor who own at least 10% of the company's outstanding shares. 62.3 percent of BioNTech SE outstanding shares that are owned by insiders signifies that they have been buying or selling the stock in recent months in anticipation of some upcoming event.
Check BioNTech Ownership Details
BioNTech SE Risk Profiles
Although BioNTech's alpha and beta are two of the key measurements used to evaluate BioNTech's performance over the market, the standard measures of volatility play an important role as well.
| Mean Deviation | 2.28 | |||
| Semi Deviation | 2.67 | |||
| Standard Deviation | 3.64 | |||
| Variance | 13.23 |
BioNTech Stock Against Markets
Be your own money manager
Our tools can tell you how much better you can do entering a position in BioNTech without increasing your portfolio risk or giving up the expected return. As an individual investor, you need to find a reliable way to track all your investment portfolios. However, your requirements will often be based on how much of the process you decide to do yourself. In addition to allowing all investors analytical transparency into all their portfolios, our tools can evaluate risk-adjusted returns of your individual positions relative to your overall portfolio.Did you try this?
Run Price Exposure Probability Now
Price Exposure ProbabilityAnalyze equity upside and downside potential for a given time horizon across multiple markets |
| All Next | Launch Module |
BioNTech Corporate Management
Elected by the shareholders, the BioNTech's board of directors comprises two types of representatives: BioNTech inside directors who are chosen from within the company, and outside directors, selected externally and held independent of BioNTech. The board's role is to monitor BioNTech's management team and ensure that shareholders' interests are well served. BioNTech's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, BioNTech's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Katalin Kariko | Senior Therapies | Profile | |
| Sylke Maas | Vice Strategy | Profile | |
| Michael Boehler | MD Communications | Profile | |
| Zach Taylor | Senior Strategy | Profile |
Additional Tools for BioNTech Stock Analysis
When running BioNTech's price analysis, check to measure BioNTech's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy BioNTech is operating at the current time. Most of BioNTech's value examination focuses on studying past and present price action to predict the probability of BioNTech's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move BioNTech's price. Additionally, you may evaluate how the addition of BioNTech to your portfolios can decrease your overall portfolio volatility.